PCM
PRTK

Palisade Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Palisade Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14,800
Closed -$77K – 408
2020
Q2 		$77K Sell
14,800
-3,000
-17% -$13.3K ﹤0.01% 383
2020
Q1 		$56K Sell
17,800
-23,000
-56% -$84.8K ﹤0.01% 418
2019
Q4 		$164K Buy
+40,800
New +$142K ﹤0.01% 405
2018
Q4 		– Sell
-13,000
Closed -$126K – 462
2018
Q3 		$126K Buy
+13,000
New +$131K ﹤0.01% 454

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Palisade Capital Management's PRTK Position: Q3 2020 in Review

Palisade Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2020, closing a stake of 14,800 shares — an estimated $77K sold.

Palisade Capital Management first reported a position in PRTK in Q3 2018 and held it in 4 quarters. The position peaked at $164K in Q4 2019. 100 funds tracked by Wall St. Rank hold PRTK as of Q3 2020.

  • Palisade Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Palisade Capital Management sold 14,800 Paratek Pharmaceuticals, Inc. shares in Q3 2020, an estimated $77K.
  • Palisade Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2018 and held it in 4 quarters.
  • Palisade Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $164K in Q4 2019.
  • 100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2020.

Based on Palisade Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.